Sandoz US News

sandoz_us_news.jpg

Sandoz enters agreement to commercialize two ready-to-use infusion products in the United States

Sandoz today announced the signing of an exclusive license and supply agreement with BioQuiddity Incorporated, a specialty pharmaceutical company, under which Sandoz has the right to market Under the agreement, BioQuiddity is responsible for obtaining the requisite regulatory approvals and supplying the unit-dose infusion systems, and Sandoz is responsible for marketing and commercializing the products. Financial details of the agreement were not disclosed.

Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mg

Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mg

FDA approves first biosimilar Zarxio™ (filgrastim-sndz) from Sandoz

FDA approves first biosimilar Zarxio™ (filgrastim-sndz) from Sandoz

Sandoz Multimedia

Multimedia_Center_300x77.jpg

Visit our multimedia gallery to learn about Sandoz.

Product Catalog

Use our Product Catalog tool to search our database for information regarding a specific Sandoz product in the US.

Sandoz Careers

sandoz_careers.jpg

Our people are our greatest resource. We are always looking for new colleagues to share in our passion and commitment to making the world a healthier place.

Slideshow Background Images